Adekemi Taylor

640 total citations
17 papers, 482 citations indexed

About

Adekemi Taylor is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Adekemi Taylor has authored 17 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Hematology. Recurrent topics in Adekemi Taylor's work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Adekemi Taylor is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Adekemi Taylor collaborates with scholars based in United States, United Kingdom and Netherlands. Adekemi Taylor's co-authors include Liliana Delgado, Timothy A. Yap, Anthony W. Tolcher, Richard D. Baird, David Olmos, Amita Patnaik, Kyriakos P. Papadopoulos, Michelle D. Garrett, Ivy Fearen and Johann S. de Bono and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Adekemi Taylor

15 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adekemi Taylor United States 4 338 142 100 88 73 17 482
Liliana Delgado United States 4 329 1.0× 132 0.9× 84 0.8× 88 1.0× 67 0.9× 6 450
Jérôme Alexandre France 3 296 0.9× 139 1.0× 174 1.7× 57 0.6× 78 1.1× 4 445
Brianne Kaiser United States 4 405 1.2× 227 1.6× 132 1.3× 104 1.2× 97 1.3× 4 607
Lorina Dudkin United States 5 506 1.5× 160 1.1× 156 1.6× 117 1.3× 89 1.2× 5 647
Elisabeth Llonch Switzerland 2 509 1.5× 214 1.5× 128 1.3× 106 1.2× 93 1.3× 2 651
B. Markman Australia 8 469 1.4× 293 2.1× 152 1.5× 88 1.0× 69 0.9× 20 688
Davide Torti Italy 12 418 1.2× 304 2.1× 116 1.2× 77 0.9× 137 1.9× 17 677
Lucia Trandafir Switzerland 11 280 0.8× 247 1.7× 272 2.7× 61 0.7× 85 1.2× 22 634
Magnus Zethoven Australia 14 213 0.6× 192 1.4× 111 1.1× 60 0.7× 145 2.0× 21 501
Louise Barys Switzerland 8 328 1.0× 157 1.1× 105 1.1× 53 0.6× 62 0.8× 12 575

Countries citing papers authored by Adekemi Taylor

Since Specialization
Citations

This map shows the geographic impact of Adekemi Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adekemi Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adekemi Taylor more than expected).

Fields of papers citing papers by Adekemi Taylor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adekemi Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adekemi Taylor. The network helps show where Adekemi Taylor may publish in the future.

Co-authorship network of co-authors of Adekemi Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Adekemi Taylor. A scholar is included among the top collaborators of Adekemi Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adekemi Taylor. Adekemi Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Li, Zhaoyang, et al.. (2025). Evaluation of pharmacokinetics of intravenous protein C concentrate in protein C deficiency: implications for treatment initiation and maintenance. Research and Practice in Thrombosis and Haemostasis. 9(3). 102859–102859.
2.
Zhou, Xiaofei, Boris Grinshpun, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 65(7). 873–884. 2 indexed citations
3.
Polireddy, Kishore, Xialin Chen, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Pharmacokinetics. 64(6). 925–942. 2 indexed citations
4.
Zhou, Xiaofei, et al.. (2025). Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 65(11). 1411–1419.
5.
Taylor, Adekemi, et al.. (2024). Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer. Clinical Pharmacokinetics. 63(10). 1477–1487. 2 indexed citations
6.
Ferron‐Brady, Geraldine, Adekemi Taylor, Kishore Polireddy, et al.. (2023). Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3. Blood. 142(Supplement 1). 6730–6730. 2 indexed citations
7.
George, Suzanne, Filip Jankú, Ping Chi, et al.. (2021). Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies. Cancer Research. 81(13_Supplement). CT123–CT123. 2 indexed citations
8.
Taylor, Adekemi, et al.. (2021). Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia. Clinical Pharmacology in Drug Development. 10(8). 918–926. 11 indexed citations
9.
10.
Yap, Timothy A., Yan Li, Amita Patnaik, et al.. (2011). First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 29(35). 4688–4695. 433 indexed citations
11.
12.
Trucksis, Michele, Evan Friedman, Adekemi Taylor, et al.. (2009). Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers. Cancer Research. 69. 3604–3604. 4 indexed citations
13.
Yap, Timothy A., Kyriakos P. Papadopoulos, Ivy Fearen, et al.. (2009). Abstract B135: First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC). Molecular Cancer Therapeutics. 8(12_Supplement). B135–B135. 1 indexed citations
14.
Taylor, Adekemi, Ali Borhan, & James S. Ultman. (2006). Three-Dimensional Simulations of Reactive Gas Uptake in Single Airway Bifurcations. Annals of Biomedical Engineering. 35(2). 235–249. 13 indexed citations
15.
Taylor, Adekemi. (2006). Three-Dimensional Computational Fluid Dynamics Simulations of Ozone Uptake in the Respiratory Tract. 2 indexed citations
16.
Taylor, Adekemi, et al.. (2005). Changes in the carbon dioxide expirogram in response to ozone exposure. Toxicology and Applied Pharmacology. 213(1). 1–9. 2 indexed citations
17.
Taylor, Adekemi, et al.. (2005). Uptake of Ozone in Human Lungs and Its Relationship to Local Physiological Response. Inhalation Toxicology. 17(13). 699–707. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liliana Delgado Breakdown of academic impact, for papers by Jérôme Alexandre Breakdown of academic impact, for papers by Brianne Kaiser Breakdown of academic impact, for papers by Lorina Dudkin Breakdown of academic impact, for papers by Elisabeth Llonch Breakdown of academic impact, for papers by B. Markman Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by Lucia Trandafir Breakdown of academic impact, for papers by Magnus Zethoven Breakdown of academic impact, for papers by Louise Barys
Rankless by CCL
2026